TerrAscend (TSNDF) Total Non-Current Liabilities (2020 - 2026)
TerrAscend's (TSNDF) quarterly Total Non-Current Liabilities came in at $390.5 million in Q1 2026, up 8.97% year-on-year from $358.3 million in Q1 2025, and up 3.18% on a QoQ basis from $378.4 million in Q4 2025.
TerrAscend (TSNDF) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 7 years of Total Non-Current Liabilities data on file, last reported at $390.5 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 8.97% year-over-year to $390.5 million in Q1 2026; TTM through Mar 2026 was $390.5 million, a 8.97% increase from a year earlier, with the FY2025 full-year figure at $378.4 million, up 11.51% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $390.5 million, up from $378.4 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for TSNDF reached as high as $390.5 million in Q1 2026 and fell as low as $218.8 million in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $319.3 million across 5 years, with a median of $339.4 million in 2024.
- Across the five-year window, Total Non-Current Liabilities slumped 32.16% in 2023 and surged 59.75% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $242.5 million in 2022, then decreased by 9.79% to $218.8 million in 2023, then soared by 55.12% to $339.4 million in 2024, then gained by 11.51% to $378.4 million in 2025, then advanced by 3.18% to $390.5 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $390.5 million in Q1 2026, $378.4 million in Q4 2025, and $383.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | TerrAscend | 160.44 Mn | 162.98 Mn | 34.60 Mn | 390.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 390.48 Mn |
| Dec 31, 2025 | 378.43 Mn |
| Sep 30, 2025 | 383.47 Mn |
| Jun 30, 2025 | 361.96 Mn |
| Mar 31, 2025 | 358.34 Mn |
| Dec 31, 2024 | 339.37 Mn |
| Sep 30, 2024 | 371.36 Mn |
| Jun 30, 2024 | 356.64 Mn |
| Mar 31, 2024 | 224.31 Mn |
| Dec 31, 2023 | 218.78 Mn |
| Sep 30, 2023 | 303.50 Mn |
| Jun 30, 2023 | 292.66 Mn |
| Mar 31, 2023 | 246.20 Mn |
| Dec 31, 2022 | 242.51 Mn |
| Sep 30, 2022 | 274.32 Mn |
| Jun 30, 2022 | 323.25 Mn |
| Mar 31, 2022 | 362.90 Mn |
| Dec 31, 2021 | 286.79 Mn |
| Dec 31, 2020 | -132.26 Mn |